BACKGROUND: Goeckerman's therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. Pentraxin 3 (PTX3) is a newly identified acute phase reactant with non redundant functions in innate immunity. PTX3 has been shown to be a reliable prognostic marker in patients with various inflammatory disorders including rheumatoid arthritis, vasculitis, and psoriasis. METHODS: The aim of this study was to evaluate the influence of Goeckerman's therapy of psoriasis on levels of two pentraxins: long pentraxin PTX3 and C reactive protein in 49 patients with chronic plaque psoriasis. CRP was assessed by immunonephelometry on IMMAGE 800 (Beckman, USA). PTX3 was detected using sandwich ELISA detection set (Alexis Biochemicals, Switzerland). RESULTS: The serum levels of both parameters (expressed as average +/- 1 SD) were significantly diminished after GT. The level of PTX3 dropped from 1.92 +/- 0.72 ng/ml before GT to 1.66 +/- 0.58 ng/ml after GT (P= 0.0396) and the level of CRP fell from 4.64 +/- 3.93 mg/l to 1.66 +/- 0.58 mg/l (P < 0.0001).Comparing to healthy controls, the serum levels of both parameters before GT were significantly higher than those found in healthy blood donors and remained significantly increased after GT. CONCLUSION: Increased serum concentrations of pentraxin 3 and CRP are alleviated by GT in patients with psoriasis.

Department of Clinical Immunology and Allergy Charles University Prague Czech Republic

000      

02193naa 2200505 a 4500

001      

bmc11006312

003      

CZ-PrNML

005      

20121106112122.0

008      

110401s2008 xxu e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Andrýs, Ctirad, $d 1962- $7 mzk2008430528

245    10

$a Goeckerman's therapy for psoriasis with special reference to serum pentraxin 3 level / $c A Ctirad, B Lenka, P David, F Zdenek, H Kveta, E Karel, K Jan

314    __

$a Department of Clinical Immunology and Allergy, Charles University, Prague, Czech Republic. andrys@lfhk.cuni.cz

520    9_

$a BACKGROUND: Goeckerman's therapy (GT) of psoriasis is based on daily application of pharmacy grade coal tar on affected skin with subsequent exposure to UV light. Pentraxin 3 (PTX3) is a newly identified acute phase reactant with non redundant functions in innate immunity. PTX3 has been shown to be a reliable prognostic marker in patients with various inflammatory disorders including rheumatoid arthritis, vasculitis, and psoriasis. METHODS: The aim of this study was to evaluate the influence of Goeckerman's therapy of psoriasis on levels of two pentraxins: long pentraxin PTX3 and C reactive protein in 49 patients with chronic plaque psoriasis. CRP was assessed by immunonephelometry on IMMAGE 800 (Beckman, USA). PTX3 was detected using sandwich ELISA detection set (Alexis Biochemicals, Switzerland). RESULTS: The serum levels of both parameters (expressed as average +/- 1 SD) were significantly diminished after GT. The level of PTX3 dropped from 1.92 +/- 0.72 ng/ml before GT to 1.66 +/- 0.58 ng/ml after GT (P= 0.0396) and the level of CRP fell from 4.64 +/- 3.93 mg/l to 1.66 +/- 0.58 mg/l (P < 0.0001).Comparing to healthy controls, the serum levels of both parameters before GT were significantly higher than those found in healthy blood donors and remained significantly increased after GT. CONCLUSION: Increased serum concentrations of pentraxin 3 and CRP are alleviated by GT in patients with psoriasis.

590    __

$a bohemika - dle Pubmed

650    _2

$a mladiství $7 D000293

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a biologické markery $x krev $7 D015415

650    _2

$a C-reaktivní protein $x analýza $7 D002097

650    _2

$a studie případů a kontrol $7 D016022

650    _2

$a chronická nemoc $7 D002908

650    _2

$a dehet uhelný $x aplikace a dávkování $7 D003033

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a keratolytika $x aplikace a dávkování $7 D007641

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a psoriáza $x krev $x terapie $7 D011565

650    _2

$a sérový amyloidový protein $x analýza $7 D000683

650    _2

$a stupeň závažnosti nemoci $7 D012720

650    _2

$a terapie ultrafialovými paprsky $7 D014467

650    _2

$a mladý dospělý $7 D055815

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Borská, Lenka $7 nlk20060173900

700    1_

$a Pohl, David $7 xx0104099

700    1_

$a Fiala, Zdeněk, $d 1955- $7 nlk19990073147

700    1_

$a Hamáková, Květoslava $7 xx0064204

700    1_

$a Ettler, Karel, $d 1957- $7 nlk19990073134

700    1_

$a Krejsek, Jan, $d 1958- $7 nlk19990073429

773    0_

$t International Journal of Dermatology $w MED00009891 $g Roč. 47, č. 10 (2008), s. 1011-1014

910    __

$a ABA008 $b x $y 2

990    __

$a 20110414103853 $b ABA008

991    __

$a 20121106112130 $b ABA008

999    __

$a ok $b bmc $g 833914 $s 698408

BAS    __

$a 3

BMC    __

$a 2008 $b 47 $c 10 $d 1011-1014 $m International journal of dermatology $n Int J Dermatol $x MED00009891

LZP    __

$a 2011-1B09/jjme